Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07561034

The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung Disease

This study evaluates the effects of a structured home exercise program in participants with pulmonary hypertension associated with interstitial lung disease. Participants will complete a defined exercise regimen over a 16-week period, and functional capacity and patient reported outcomes will be assessed at baseline and after the intervention. The study aims to determine whether a home-based exercise approach is feasible and associated with improvements in functional performance.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Rochester Medical Center

Rochester, New York, 14642, United States

Location status: Recruiting

Location contact

Daniel Lachant, DO

CONTACT

[email protected]

5852734608

Daniel Lachant, DO

PRINCIPAL_INVESTIGATOR

About this study

Pulmonary hypertension associated with interstitial lung disease is associated with reduced exercise capacity, decreased quality of life, and increased morbidity. Exercise based interventions may improve functional status in this population; however, access to supervised rehabilitation programs may be limited. Home based exercise programs offer a potentially accessible alternative, but their feasibility and effectiveness in this population are not well established.

In this interventional study, participants with pulmonary hypertension associated with interstitial lung disease will be enrolled and assigned to a structured home exercise program. The intervention will be performed over a 16-week period. Participants will undergo baseline assessments prior to starting the exercise program and follow up assessments at the end of the intervention period.

Assessments will include measures of functional capacity and patient reported outcomes collected using standardized methods. The primary objective is to evaluate changes in functional performance following completion of the home exercise program. Secondary objectives include evaluation of participant reported outcomes and feasibility of the intervention.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Follows at University of Rochester Medical Center Pulmonary Hypertension Clinic.
  • Adult patients (>18 years old) with right heart catheterization confirmed pulmonary hypertension interstitial lung disease on stable therapy dosing for at least 30 days.
  • Access to a smart phone or email to receive daily messages.
  • Clinically stable by the investigator.

Exclusion criteria

  • Pregnancy.
  • Pulmonary Hypertension Groups 1,2,4,5.
  • Resting tachycardia >120 beats/m during screening.
  • Inability to walk.
  • WHO Functional Class IV
  • Lack of access to email or text messaging.
  • Participating in a rehabilitation program.

Treatment and study plan

Home Exercise Program, Aerobic Plus Strength Training

Behavioral

Structured home based exercise program delivered by daily SMS text message or email for 16 weeks, including aerobic and strength training activities with heart rate guidance.

Home Exercise Program, Aerobic Only

Behavioral

Structured home based exercise program delivered by daily SMS text message or email for 16 weeks, including aerobic activities with heart rate guidance.

Primary outcomes

  1. Mean Change in Cardiac Effort From Baseline to 16 Weeks

    Time frame: Baseline to 16 weeks

    Cardiac Effort is measured as the ratio of the total number of heart beats recorded during the Six Minute Walk Test to the total distance walked in meters. Heart rate is continuously monitored during the test using a validated heart rate monitoring device. The value represents the number of heart beats required per unit distance walked (beats per meter). Individual participant values are calculated at baseline and at 16 weeks. The outcome is defined as the mean change in Cardiac Effort from baseline to 16 weeks across participants. Lower values indicate improved cardiac efficiency and better functional performance, while higher values indicate reduced efficiency and worse functional status.

Secondary outcomes

  1. Mean Change in Six Minute Walk Distance From Baseline to 16 Weeks

    Time frame: Baseline to 16 weeks

    Six Minute Walk Distance is measured using the standardized Six Minute Walk Test according to established clinical guidelines. The total distance walked in meters during six minutes is recorded for each participant. Individual participant values are collected at baseline and at 16 weeks. The outcome is defined as the mean change in distance walked from baseline to 16 weeks across participants. Higher values indicate improved functional capacity, while lower values indicate reduced exercise tolerance.

  2. Mean Change in emPHasis-10 Score From Baseline to 16 Weeks

    Time frame: Baseline to 16 weeks post intervention

    Quality of life is measured using the emPHasis-10 questionnaire, a validated patient reported outcome instrument specific to pulmonary hypertension. The questionnaire consists of 10 items assessing symptoms and impact on daily life. Scores range from 0 to 50, with higher scores indicating worse health related quality of life. Individual participant scores are calculated by summing item responses. The outcome is defined as the mean change in total score from baseline to 16 weeks across participants.

  3. Mean Change in King's Brief Interstitial Lung Disease Questionnaire Score From Baseline to 16 Weeks

    Time frame: Baseline to 16 weeks

    Quality of life is measured using the King's Brief Interstitial Lung Disease questionnaire, a validated instrument assessing health status in interstitial lung disease. Scores range from 0 to 100, with higher scores indicating better health status. Individual participant scores are calculated according to standard scoring procedures. The outcome is defined as the mean change in score from baseline to 16 weeks across participants.

  4. Mean Change in Lower Extremity Muscle Strength From Baseline to 16 Weeks

    Time frame: Baseline to 16 weeks

    Muscle strength is measured using a Lafayette Muscle Dynamometer for quadriceps strength and a Jamar Hand Dynamometer for hand grip strength. Measurements are recorded in pounds (lbs) for each participant. Individual participant values are obtained at baseline and at 16 weeks. The outcome is defined as the mean change in muscle strength from baseline to 16 weeks across participants. Higher values indicate greater muscle strength, while lower values indicate reduced strength.

  5. Number of Participants With Healthcare Utilization Events During the 16 Week Study Period

    Time frame: From enrollment to 16 weeks

    Healthcare utilization events include unplanned medical visits such as emergency department visits, hospitalizations, and clinic visits occurring during the study period. Events are collected through participant self report and study follow up. The outcome is defined as the number of participants experiencing at least one healthcare utilization event during the study period.

  6. Number of Participants With Falls During the 16 Week Study Period

    Time frame: From enrollment to 16 weeks

    Falls are defined as any unintentional event resulting in a participant coming to rest on the ground or a lower level. Falls are self reported by participants during weekly check-ins throughout the study period. The outcome is defined as the number of participants experiencing at least one fall during the study period.

Study contacts

Contact information is provided by the study sponsor or research team.

Daniel Lachant, DO

CONTACT

[email protected]

585 273 4608

Sponsors and collaborators

Lead sponsor

University of Rochester

Other

Collaborators

  • Liquidia Technologies, Inc.

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
May 1, 2026
Registry last updated
Jul 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.